Abstract
25997 Safety of tildrakizumab 100 mg and 200 mg through 5 years of exposure in reSURFACE 1
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have